Close menu




PAION O.N

Photo credits: pixabay.com

Commented by Stefan Feulner on January 14th, 2022 | 11:44 CET

BioNTech, Defence Therapeutics, PAION - Seizing the momentum

  • Biotechnology

The Corona pandemic brought biotechnology to the forefront of society's consciousness, especially since the first vaccines were created in German laboratories. However, the biotech spectrum is much broader than pandemic vaccine research. In addition to research in medicine, the sector is playing an increasingly important role in environmental protection, agriculture and the ongoing climate change.

Read

Commented by Armin Schulz on September 6th, 2021 | 12:17 CEST

Paion, Diamcor, DeFi Technologies - This is where the music plays

  • Diamonds

After the Fed announcements, the DAX and Dow moved sideways, despite a rise at the beginning of last week. Many stocks in these indices are now also considered fundamentally expensive if one follows the standard work of fundamental analysis by the Graham and Dodd Model, which roughly speaking sees a fair value for stocks with a price-earnings ratio of a maximum of 15. If you want to bring performance into your portfolio, you need stocks that are not in the direct focus of analysts. If there is an interesting story behind it, you can get a booster in your portfolio at an early stage. Today, we highlight three shares with interesting news and stories.

Read

Commented by Carsten Mainitz on July 12th, 2021 | 10:07 CEST

CureVac, XPhyto Therapeutics, Paion - Where are the turning points?

  • Biotechnology

"Opportunity and risk are two sides of the same coin", that is to say, with great potential returns, there is also the risk of incurring significant price losses. The biotechnology sector, in particular, offers investors a broad universe in which to find lucrative investments. We present three exciting ideas below. Who is winning the race?

Read

Commented by Carsten Mainitz on March 30th, 2021 | 11:23 CEST

Paion, PsyBio Therapeutics, NanoRepro - New dimensions

  • Biotechnology

When companies enter previously uncharted territory with new solutions or innovations, it can lead to a profound revaluation of the share. The potential associated with the new activities is usually priced in over a more extended period, sometimes with high fluctuations. We present three companies that are currently going through the exciting phase of a revaluation.

Read

Commented by Mario Hose on June 2nd, 2020 | 05:58 CEST

Memphasys, Moderna, Paion - Investments in solutions with potential

  • Healthcare

Biotech companies around the world employ scientists and physicians to study the causes of diseases. The research and development of medical products and solutions usually involves a large number of tests and takes a correspondingly long time. The longer and more extensive this process is, the more capital these companies require from investors. In the race to bring to market preparations or products that improve people's well-being or fulfill desires, the providers of solutions usually have great sales potential and investors may be bought out through a takeover.

Read